Namilumab

Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis[1].

Product Specifications

CAS Number

[1206681-39-1]

Product Name Alternative

AMG-203; Anti-Human CSF2 Recombinant Antibody

UNSPSC

12352203

Target

C-Fms

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/namilumab.html

Purity

99.47

Solubility

H2O

Smiles

[Namilumab]

Molecular Weight

(145.78 kDa)

References & Citations

[1]Huizinga TWJ, et, al. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis Res Ther. 2017 Mar 9;19 (1) :53.